Investec appointed as Financial Adviser and Joint Corporate Broker to NIOX Group plc

NIOX Group plc logo

 

Our role

Investec has been appointed as Financial Adviser and Joint Corporate Broker to NIOX Group plc, the company dedicated to improving asthma diagnosis and management through the provision of its FeNO (fractional exhaled nitric oxide) testing devices and consumables globally. As at 17 January 2024 it has a market capitalisation of c.£263.5m.

Investec has been appointed to promote NIOX’s equity story, broaden its shareholder register, and support the Group’s growth ambitions by providing strategic advice.

About NIOX Group

NIOX Group is a global provider of FeNO (fractional exhaled nitric oxide) testing devices and consumables, mainly to hospitals, outpatient and primary care clinics and CROs.

FeNO is a precise biomarker for airway inflammation in asthma and a FeNO test provides 7x greater chance of a correct diagnosis. The measurement of FeNO is quick and non-invasive. Regular testing can predict and help prevent exacerbations by 50%. FeNO testing is recommended in global guidelines and promoted by national programmes for example the NHS FeNO programme.